Tactile Systems Technology Balances Growth With New Risks

Tactile Systems Technology ((TCMD)) has held its Q4 earnings call. Read on for the main highlights of the call.

Tactile Systems Technology’s latest earnings call painted a picture of solid momentum tempered by emerging regulatory uncertainty. Executives highlighted double‑digit revenue growth, improving margins, strong cash generation and a deepening innovation pipeline, while acknowledging that new Medicare prior‑authorization rules could briefly slow growth but should not derail the long‑term trajectory.

Revenue Growth Underscores Durable Demand

Full‑year 2025 revenue climbed 12% to $329.5 million, underscoring healthy demand across the portfolio. Management framed this as evidence that the company’s core lymphedema franchise and newer offerings are scaling together, providing a more balanced growth engine.

Q4 Surge Led by Lymphedema and Airway Clearance

Fourth‑quarter revenue jumped 21% year over year to $103.6 million, with lymphedema sales up 16% to $89.5 million and airway‑clearance revenue soaring 66% to $14.1 million. The mix shift toward higher‑growth segments helped showcase the company’s ability to expand beyond its legacy base while keeping its flagship category growing.

Margins Expand as Profitability Steps Higher

Gross margin for 2025 expanded 190 basis points to 75.9%, and Q4 gross margin improved to 78.2% from 75.2% a year earlier. Adjusted EBITDA rose 21% to $44.8 million for the year, with Q4 adjusted EBITDA of $22.0 million versus $16.2 million, signaling growing operating leverage despite ongoing investment.

Robust Cash Generation and Balance Sheet De‑Risking

The company generated nearly $43 million in operating cash flow during 2025, providing ample flexibility for capital deployment. Management used that cash to repay $26.3 million of term debt, repurchase $26.5 million of stock and end the year with $83.4 million in cash and no outstanding borrowings.

Salesforce Buildout Boosts Commercial Execution

Tactile hit its year‑end sales‑rep hiring target and implemented a one‑to‑one structure pairing account managers with product specialists. The team reported better sales productivity supported by broader adoption of a new CRM system, suggesting that the enlarged commercial footprint is beginning to translate into higher output per rep.

Airway‑Clearance Business Accelerates Rapidly

AffloVest airway‑clearance sales surged 66% year over year in Q4 and grew 6% sequentially, marking it as a major incremental growth driver. Management argued that these results confirm a market‑leading position in airway clearance, helping diversify revenue away from a single therapeutic area.

LymphaTech Acquisition Expands Technology and TAM

The announced acquisition of LymphaTech brings 3D digital scanning for fluid measurement and monitoring into Tactile’s toolkit. Executives emphasized that the immediately commercialized product broadens the portfolio and supports total addressable market expansion toward an estimated 20 million symptomatic but undiagnosed U.S. patients.

Clinical Evidence Strengthens Reimbursement Position

Two‑month randomized controlled trial results for Flexitouch Plus were published, and a six‑month manuscript has been submitted for review. Management said this growing evidence base enhances the device’s clinical value story and supports ongoing discussions with payers, particularly in head‑and‑neck lymphedema.

Product Roadmap Signals Ongoing Innovation

The company introduced Nimbl and believes it has achieved leadership in basic compression pumps, broadening its reach across disease severity. It also submitted a 510(k) for a next‑generation AffloVest and is planning phased Flexitouch upgrades aimed at making the system smaller, lighter and more connected.

Technology Investments Target Operating Efficiency

Beyond commercial tools, Tactile has rolled out a CRM platform and completed phase one of an AI‑driven system for order intake and medical‑record review. These capabilities are expected to speed patients’ time to therapy, reduce documentation errors and enhance back‑office efficiency over time.

Medicare Prior Authorization Poses Temporary Headwind

CMS’s new prior‑authorization requirement for pneumatic compression devices, effective April 13, 2026, loomed large on the call as a near‑term risk. Management expects added administrative steps and a temporary market impact but stressed that these assumptions are already embedded in the company’s 2026 outlook.

Moderated 2026 Revenue Outlook

Guidance for 2026 revenue of $357 million to $365 million implies 8% to 11% growth, a step down from 2025’s pace due mainly to regulatory headwinds. The range reflects uncertainty over how disruptive the prior‑authorization process will be, even as both lymphedema and airway‑clearance segments are still expected to grow at similar high‑single‑digit to low‑double‑digit rates.

Operating Expense Growth Weighs on Near‑Term Margins

Fourth‑quarter GAAP operating expenses rose 20% to $62.2 million, driven by higher sales and marketing spending and increased research, general and administrative costs. Management noted these investments will fully annualize into 2026, contributing to margin moderation even as they support future growth.

Higher Tax Burden Dampens Net Income Growth

Income tax expense climbed 169% year over year to $8.8 million, partially offsetting gains in operating income. The higher tax load illustrates that not all of the company’s improved profitability is flowing through to the bottom line, a factor investors will need to watch in coming quarters.

Cash Down Modestly as Capital Is Deployed

Cash and equivalents ended the year at $83.4 million, down from $94.4 million in the prior‑year period, reflecting debt repayment and share repurchases. While the balance declined, leverage fell to zero, leaving Tactile with a cleaner balance sheet and financial capacity for future strategic moves.

Guidance Points to Steady Growth Amid Regulatory Change

For 2026, Tactile expects revenue of $357 million to $365 million, GAAP gross margin around 76% and GAAP operating expenses up roughly 8% to 10% year over year. The company forecast net interest income of about $3 million, a 28% tax rate, 22 to 23 million diluted shares and adjusted EBITDA of $49 million to $51 million, incorporating a short‑term Medicare prior‑authorization impact but assuming growth resumes afterward.

Tactile Systems Technology’s earnings call showcased a company balancing strong current execution with cautious planning for regulatory change. Revenue growth, margin expansion, innovation and a strengthened balance sheet provide a solid base, while investors will be watching how efficiently Tactile navigates Medicare’s new rules and converts its recent investments into sustained earnings power.